Zusammenfassung
Hintergrund
Immun-Checkpoint-Inhibitoren (ICIs) haben die Behandlungsmöglichkeiten von verschiedenen malignen Erkrankungen wesentlich verändert, indem sie Einfluss auf das Immunsystem nehmen und Tumorzellen sich nicht mehr der Immunüberwachung entziehen können. Neben diesem erwünschten Effekt können immunvermittelte Nebenwirkungen (irAE) in fast jedem Organsystem und damit auch rheumatologische-irAE (rh-irAE) auftreten.
Fragestellung
Rh-irAE sind bisher in verschiedenen Veröffentlichungen beschrieben und anhand dieses Reviews erstmals untersucht worden. Ziel ist es, einen Überblick über die Prävalenzen, Schweregerade, Therapiemöglichkeiten und das Tumoransprechen bei Patienten mit rh-irAE zu geben.
Material und Methoden
Wir führten bis Januar 2020 eine Literaturrecherche nach dem PICO-Modell in PubMed durch, in der Studien und Fallberichte zu rh-irAE unter ICI-Therapie beschrieben wurden.
Ergebnisse
Es wurden 18 Originalarbeiten eingeschlossen, größtenteils klinische Studien (n = 13) und wichtige Fallberichte (n = 5). Rh-irAE treten in verschiedenen Erscheinungsformen auf, wobei es am häufigsten zu Arthralgien, Arthritiden und Myositiden kommt. Vaskulitiden, Sarkoidose oder Kollagenosen werden seltener beschrieben. Die publizierte Prävalenz von rh-irAE variiert, es werden Prävalenzen zwischen 2,3 und 6,6 % angegeben Die Therapie richtet sich primär nach dem Schweregrad der Nebenwirkung und beinhaltet in den meisten Fällen nichtsteroidale Antirheumatika und Kortikosteroide, in wenigen Fällen auch konventionelle DMARDs wie MTX oder biologische DMARDs. Das Tumoransprechen ist bei Patienten mit rheumatologischen Nebenwirkungen höher im Vergleich zu Patienten ohne Nebenwirkungen.
Diskussion
Eine frühzeitige Erkennung von rh-irAE ist wichtig, um diese rechtzeitig zu behandeln. Weitere prospektive Untersuchungen sind nötig um rh-irAE systematisch zu untersuchen.
Abstract
Background
Immune checkpoint inhibitors (ICI) have essentially improved the treatment options for various malignant diseases. They lead to an activation of the immune system and subsequent attack of tumor cells by affecting the immune system and preventing tumor cells from avoiding detection. In addition to this desired effect, immune-related adverse events (irAE) can occur in nearly all organ systems and therefore also rheumatological irAE (rh-irAE).
Objective
The occurrence of rh-irAE has been described in various publications and is specifically investigated in this review. The aim is to provide an overview on the prevalence, severity, treatment options and altered tumor response in patients with rh-irAE.
Material and methods
We conducted a literature search for studies and case reports on rh-irAE under ICI therapy in PubMed up to January 2020 using the PICO model.
Results
A total of 18 publications were included, most of which were clinical studies (n = 13) and the rest case reports (n = 5). Several rh-irAE can occur with a wide variety of manifestations of which arthralgia, arthritis and myositis were the most common. Other rheumatic diseases, such as vasculitis, connective tissue diseases and sarcoidosis were less frequently described. The published prevalence of rh-irAE varied with a prevalence between 2.3% and 6.6%. Treatment of rh-irAE depends on the severity and most patients receive nonsteroidal anti-inflammatory drugs and glucocorticosteroids. In some cases, conventional DMARDs, such as methotrexate and biological DMARDs, were administered. Patients with rh-irAE in general had a higher tumor response rate compared to patients without side effects.
Conclusion
A close observation of patients and early detection of rh-irAE are important in order to treat these side effects in time. Further prospective studies are necessary to systematically investigate rh-irAE.
Literatur
Abdel-Wahab N, Shah M, Lopez-Olivo MA, Suarez-Almazor ME (2018) Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting Autoimmune disease: a systematic review. Ann Intern Med 168:121. https://doi.org/10.7326/M17-2073
Belkhir R, Burel SL, Dunogeant L, Marabelle A, Hollebecque A, Besse B, Leary A, Voisin A‑L, Pontoizeau C, Coutte L, Pertuiset E, Mouterde G, Fain O, Lambotte O, Mariette X (2017) Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment. Ann Rheum Dis 76:1747–1750. https://doi.org/10.1136/annrheumdis-2017-211216
Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner JM, Ginex P, Hallmeyer S, Holter Chakrabarty J, Leighl NB, Mammen JS, McDermott DF, Naing A, Nastoupil LJ, Phillips T, Porter LD, Puzanov I, Reichner CA, Santomasso BD, Seigel C, Spira A, Suarez-Almazor ME, Wang Y, Weber JS, Wolchok JD, Thompson JA, National Comprehensive Cancer Network (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 36:1714–1768. https://doi.org/10.1200/JCO.2017.77.6385
Buchbinder EI, Desai A (2016) CTLA‑4 and PD‑1 pathways. Am J Clin Oncol 39:98–106. https://doi.org/10.1097/COC.0000000000000239
Buder-Bakhaya K, Benesova K, Schulz C, Anwar H, Dimitrakopoulou-Strauss A, Weber TF, Enk A, Lorenz H‑M, Hassel JC (2018) Characterization of arthralgia induced by PD‑1 antibody treatment in patients with metastasized cutaneous malignancies. Cancer Immunol Immunother 67:175–182. https://doi.org/10.1007/s00262-017-2069-9
Calabrese C, Kirchner E, Kontzias K, Velcheti V, Calabrese LH (2017) Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity. RMD Open. https://doi.org/10.1136/rmdopen-2016-000412
Cappelli LC, Gutierrez AK, Baer AN, Albayda J, Manno RL, Haque U, Lipson EJ, Bleich KB, Shah AA, Naidoo J, Brahmer JR, Le D, Bingham CO (2017) Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis 76:43–50. https://doi.org/10.1136/annrheumdis-2016-209595
Cappelli LC, Brahmer JR, Forde PM, Le DT, Lipson EJ, Naidoo J, Zheng L, Bingham CO, Shah AA (2018) Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen. Semin Arthritis Rheum 48:553–557. https://doi.org/10.1016/j.semarthrit.2018.02.011
Daxini A, Cronin K, Sreih AG (2018) Vasculitis associated with immune checkpoint inhibitors—a systematic review. Clin Rheumatol 37:2579–2584. https://doi.org/10.1007/s10067-018-4177-0
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247. https://doi.org/10.1016/j.ejca.2008.10.026
Fachgruppe Molekulare Urologie der Arbeitsgruppe urologische Forschung (AuF) der Deutschen Gesellschaft für Urologie, Roos FC, Becker C, Stope MB, Tsaur I (2018) Systemische Immuncheckpoint-Inhibition: Eine vielversprechende Therapie urologischer Tumoren? Urologe 57:583–590. https://doi.org/10.1007/s00120-018-0622-6
Feist J, Murray A, Skapenko A, Schulze-Koops H (2019) A rare side effect of checkpoint inhibitor therapy-nivolumab-induced axial polyarthritis of the facet and costovertebral joints. Arthritis Rheumatol 71:1823. https://doi.org/10.1002/art.41036
Goldstein BL, Gedmintas L, Todd DJ (2014) Drug-associated polymyalgia rheumatica/giant cell arteritis occurring in two patients after treatment with ipilimumab, an antagonist of CTLA‑4. Arthritis Rheumatol 66:768–769. https://doi.org/10.1002/art.38282
Jamal S, Hudson M, Fifi-Mah A, Ye C (2019) Immune-related adverse events associated with cancer immunotherapy: a review for the practicing rheumatologist. J Rheumatol. https://doi.org/10.3899/jrheum.190084
Kim ST, Tayar J, Trinh VA, Suarez-Almazor M, Garcia S, Hwu P, Johnson DH, Uemura M, Diab A (2017) Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series. Ann Rheum Dis 76:2061–2064. https://doi.org/10.1136/annrheumdis-2017-211560
Kimura T, Fukushima S, Miyashita A, Aoi J, Jinnin M, Kosaka T, Ando Y, Matsukawa M, Inoue H, Kiyotani K, Park J, Nakamura Y, Ihn H (2016) Myasthenic crisis and polymyositis induced by one dose of nivolumab. Cancer Sci 107:1055–1058. https://doi.org/10.1111/cas.12961
Kostine M, Rouxel L, Barnetche T, Veillon R, Martin F, Dutriaux C, Dousset L, Pham-Ledard A, Prey S, Beylot-Barry M, Daste A, Gross-Goupil M, Lallier J, Ravaud A, Forcade E, Bannwarth B, Truchetet M‑E, Richez C, Mehsen N, Schaeverbeke T, FHU ACRONIM (2018) Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study. Ann Rheum Dis 77:393–398. https://doi.org/10.1136/annrheumdis-2017-212257
Kostine M, Finckh A, Bingham CO, Visser K, Leipe J, Schulze-Koops H, Choy EH, Benesova K, Radstake TRDJ, Cope AP, Lambotte O, Gottenberg J‑E, Allenbach Y, Visser M, Rusthoven C, Thomasen L, Jamal S, Marabelle A, Larkin J, Haanen JBAG, Calabrese LH, Mariette X, Schaeverbeke T (2020) EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2020-217139
Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, Ferrucci PF, Hill A, Wagstaff J, Carlino MS, Haanen JB, Maio M, Marquez-Rodas I, McArthur GA, Ascierto PA, Long GV, Callahan MK, Postow MA, Grossmann K, Sznol M, Dreno B, Bastholt L, Yang A, Rollin LM, Horak C, Hodi FS, Wolchok JD (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:23–34. https://doi.org/10.1056/NEJMoa1504030
Le Burel S, Champiat S, Mateus C, Marabelle A, Michot J‑M, Robert C, Belkhir R, Soria J‑C, Laghouati S, Voisin A‑L, Fain O, Mékinian A, Coutte L, Szwebel T‑A, Dunogeant L, Lioger B, Luxembourger C, Mariette X, Lambotte O (2017) Prevalence of immune-related systemic adverse events in patients treated with anti-programmed cell death 1/anti-programmed cell death-ligand 1 agents: a single-centre pharmacovigilance database analysis. Eur J Cancer 82:34–44. https://doi.org/10.1016/j.ejca.2017.05.032
Lidar M, Giat E, Garelick D, Horowitz Y, Amital H, Steinberg-Silman Y, Schachter J, Shapira-Frommer R, Markel G (2018) Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors. Autoimmun Rev 17:284–289. https://doi.org/10.1016/j.autrev.2018.01.003
Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, Shabafrouz K, Ribi C, Cairoli A, Guex-Crosier Y, Kuntzer T, Michielin O, Peters S, Coukos G, Spertini F, Thompson JA, Obeid M (2019) Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol 16:563–580. https://doi.org/10.1038/s41571-019-0218-0
Menzies AM, Johnson DB, Ramanujam S, Atkinson VG, Wong ANM, Park JJ, McQuade JL, Shoushtari AN, Tsai KK, Eroglu Z, Klein O, Hassel JC, Sosman JA, Guminski A, Sullivan RJ, Ribas A, Carlino MS, Davies MA, Sandhu SK, Long GV (2017) Anti-PD‑1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol 28:368–376. https://doi.org/10.1093/annonc/mdw443
Naidoo J, Cappelli LC, Forde PM, Marrone KA, Lipson EJ, Hammers HJ, Sharfman WH, Le DT, Baer AN, Shah AA, Albayda J, Manno RL, Haque U, Gutierrez AK, Bingham CO, Brahmer JR (2017) Inflammatory arthritis: a newly recognized adverse event of immune checkpoint blockade. Oncologist 22:627–630. https://doi.org/10.1634/theoncologist.2016-0390
Pérez-De-Lis M, Retamozo S, Flores-Chávez A, Kostov B, Perez-Alvarez R, Brito-Zerón P, Ramos-Casals M (2017) Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry). Expert Opin Drug Saf 16:1255–1271. https://doi.org/10.1080/14740338.2017.1372421
Postow MA, Callahan MK, Wolchok JD (2015) Immune checkpoint blockade in cancer therapy. J Clin Oncol 33:1974–1982. https://doi.org/10.1200/JCO.2014.59.4358
Ribas A (2012) Tumor immunotherapy directed at PD‑1. N Engl J Med 366:2517–2519. https://doi.org/10.1056/NEJMe1205943
Ribas A, Wolchok JD (2018) Cancer immunotherapy using checkpoint blockade. Science 359:1350–1355. https://doi.org/10.1126/science.aar4060
Richter MD, Crowson C, Kottschade LA, Finnes HD, Markovic SN, Thanarajasingam U (2019) Rheumatic syndromes associated with immune checkpoint inhibitors: a single-center cohort of sixty-one patients. Arthritis Rheumatol 71:468–475. https://doi.org/10.1002/art.40745
Salem J‑E, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A, Gobert A, Spano J‑P, Balko JM, Bonaca MP, Roden DM, Johnson DB, Moslehi JJ (2018) Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol 19:1579–1589. https://doi.org/10.1016/S1470-2045(18)30608-9
Sato K, Mano T, Iwata A, Toda T (2019) Neurological and related adverse events in immune checkpoint inhibitors: a pharmacovigilance study from the Japanese Adverse Drug Event Report database. J Neurooncol 145:1–9. https://doi.org/10.1007/s11060-019-03273-1
Schadendorf D, Wolchok JD, Hodi FS, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob J‑J, Cowey CL, Lao CD, Chesney J, Robert C, Grossmann K, McDermott D, Walker D, Bhore R, Larkin J, Postow MA (2017) Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: a pooled analysis of randomized phase II and III trials. J Clin Oncol 35:3807–3814. https://doi.org/10.1200/JCO.2017.73.2289
Shao K, McGettigan S, Elenitsas R, Chu EY (2018) Lupus-like cutaneous reaction following pembrolizumab: an immune-related adverse event associated with anti-PD‑1 therapy. J Cutan Pathol 45:74–77. https://doi.org/10.1111/cup.13059
Smith MH, Bass AR (2019) Arthritis after cancer immunotherapy: symptom duration and treatment response. Arthritis Care Res 71:362–366. https://doi.org/10.1002/acr.23467
Spain L, Diem S, Larkin J (2016) Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev 44:51–60. https://doi.org/10.1016/j.ctrv.2016.02.001
Suzuki S, Ishikawa N, Konoeda F, Seki N, Fukushima S, Takahashi K, Uhara H, Hasegawa Y, Inomata S, Otani Y, Yokota K, Hirose T, Tanaka R, Suzuki N, Matsui M (2017) Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology 89:1127–1134. https://doi.org/10.1212/WNL.0000000000004359
Tan RYC, Toh CK, Takano A (2017) Continued response to one dose of nivolumab complicated by myasthenic crisis and myositis. J Thorac Oncol 12:e90–e91. https://doi.org/10.1016/j.jtho.2017.02.024
Tetzlaff MT, Nelson KC, Diab A, Staerkel GA, Nagarajan P, Torres-Cabala CA, Chasen BA, Wargo JA, Prieto VG, Amaria RN, Curry JL (2018) Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients. J Immunother Cancer. https://doi.org/10.1186/s40425-018-0323-0
Touat M, Maisonobe T, Knauss S, Ben Hadj Salem O, Hervier B, Auré K, Szwebel T‑A, Kramkimel N, Lethrosne C, Bruch J‑F, Laly P, Cadranel J, Weiss N, Béhin A, Allenbach Y, Benveniste O, Lenglet T, Psimaras D, Stenzel W, Léonard-Louis S (2018) Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer. Neurology 91:e985–e994. https://doi.org/10.1212/WNL.0000000000006124
Zitouni NB, Arnault J‑P, Dadban A, Attencourt C, Lok CC, Chaby G (2019) Subacute cutaneous lupus erythematosus induced by nivolumab: two case reports and a literature review. Melanoma Res 29:212–215. https://doi.org/10.1097/CMR.0000000000000536
GBG (2017) NCI common terminology criteria for adverse events (CTCAE). https://www.gbg.de/de/rechner/ctcae.php. Zugegriffen: 27. Dez. 2019
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
S.H. Verspohl, H. Schulze-Koops, A. Heine und V.S. Schäfer geben an, dass kein Interessenkonflikt besteht.
Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.
Additional information
Redaktion
U. Müller-Ladner, Bad Nauheim
U. Lange, Bad Nauheim
Rights and permissions
About this article
Cite this article
Verspohl, S.H., Schulze-Koops, H., Heine, A. et al. Prävalenz und Therapie von rheumatologischen Nebenwirkungen bei Immun-Checkpoint-Inhibitor-Therapie. Z Rheumatol 79, 797–808 (2020). https://doi.org/10.1007/s00393-020-00873-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00393-020-00873-5
Schlüsselwörter
- Immun-Checkpoint-Inhibitoren
- Rheumatologische Erkrankungen
- Nebenwirkungen
- Therapie
- Autoimmunerkrankungen